A randomized, double-blind, placebo controlled, multicenter, phase 3, pivotal study with an open-label extension period to evaluate the efficacy and safety of rozanolixizumab in adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD)

13886MOG001OpenA randomized, double-blind, placebo controlled, multicenter, phase 3, pivotal study with an open-label extension period to evaluate the efficacy and safety of rozanolixizumab in adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD)NCT05063162IndustrialAdultTreatmentOtherOsborne, BenjaminGeorgetown University Medical Center : Daniel Bustamante; Lombardi Comprehensive Cancer Center : Daniel BustamanteGUMC Neurology15435Daniel BustamanteDaniel Bustamantedb1621@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>